Skip to main content

Table 1 Demographic and clinical characteristics

From: Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

Characteristic

Second-line therapy

Total*

Abiraterone acetate plus prednisone

Cabazitaxel plus prednisone

Age

N = 149

N = 100

N = 44

Median (range), years

72.6

(49.0–89.6)

73.9

(50.9–89.6)

69.7

(51.4–84.4)

≥75 years, n (%)

62 (41.6)

47 (47.0)

13 (29.5)

Prostate-specific antigen

N = 147

N = 99

N = 43

Median (range), ng/ml

60.0

(0.9–3846.0)

42.8

(1.2–3222.0)

74.6

(0.9–3846.0)

Gleason score, n (%)

N = 139

N = 92

N = 41

Median (range)

7 (4–10)

7 (4–10)

8 (6–10)

≤6, n/N (%)

27 (19.7)

24 (26.1)

2 (4.9)

=7, n (%)

47 (34.3)

30 (32.6)

17 (41.5)

≥8, n/N (%)

63 (46.0)

38 (41.3)

22 (53.7)

ECOG performance status, n (%)

N = 122

N = 79

N = 40

0

31 (25.4)

22 (27.8)

7 (17.5)

1

70 (57.4)

46 (58.2)

24 (60.9)

2

20 (16.4)

10 (12.7)

9 (22.5)

3

0 (0.0)

0 (0.0)

0 (0.0)

4

1 (0.8)

1 (1.3)

0 (0.0)

Disease location, n (%)

N = 150

N = 100

N = 44

Bone metastases

119 (79.9)

76 (76.0)

40 (90.9)

Visceral metastases

35 (23.5)

24 (24.0)

9 (20.5)

Main current comorbidities

N = 150

N = 100

N = 44

Hypertension

80 (53.3)

52 (52.0)

26 (59.1)

Any cardiovascular disorder

22 (14.7)

18 (18.0)

3 (6.8)

Diabetes mellitus

26 (17.3)

17 (17.0)

8 (18.2)

Anemia

N = 147

N = 97

N = 44

Yes, n (%)

31 (21.1)

16 (16.5)

15 (34.1)

LDH increased

N = 130

N = 85

N = 39

Yes, n (%)

80 (61.5)

45 (52.9)

31 (79.5)

Alkaline phosphatase increased

N = 140

N = 93

N = 41

Yes, n (%)

58 (41.4)

32 (34.4)

24 (58.5)

  1. ECOG, Eastern Cooperative Oncology Group; N, number of evaluable patients for each variable and group
  2. *Patients receiving treatments other than abiraterone acetate or cabazitaxel are not presented, but are included in the total sample. Therefore, the total sample is not only comprised of the pool of abiraterone acetate and cabazitaxel groups